Ken Griffin Allovir, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$0.72 - $0.82 $576 - $656	800 Added 34.78%	3,100 $2,000
Q1 2024 May 15, 2024	SELL	$0.64 - $0.78 $3,008 - $3,666	-4,700 Reduced 67.14%	2,300 $1,000
Q4 2023 Feb 14, 2024	SELL	$0.68 - $2.39 $13,600 - $47,800	-20,000 Reduced 74.07%	7,000 $4,000
Q3 2023 Nov 14, 2023	BUY	$2.15 - $3.64 $31,605 - $53,508	14,700 Added 119.51%	27,000 $58,000
Q2 2023 Aug 14, 2023	SELL	$3.17 - $5.82 $56,109 - $103,014	-17,700 Reduced 59.0%	12,300 $41,000
Q1 2023 May 15, 2023	BUY	$3.94 - $7.05 $55,948 - $100,110	14,200 Added 89.87%	30,000 $118,000
Q4 2022 Feb 14, 2023	SELL	$4.7 - $9.98 $32,900 - $69,860	-7,000 Reduced 30.7%	15,800 $81,000
Q3 2022 Nov 14, 2022	BUY	$4.13 - $8.79 $94,164 - $200,411	22,800 New	22,800 $180,000

46.5M

201K

3.1K

Ticker ALVR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,063,400
Market Cap $72.6M
Description
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.